He has a lifetime appointment. He doesn't have to fear anybody. Once Fallon makes decisions, (Merck) can't say it's some strange judge in some strange place.
Quotes about merck (16 Quotes)
What you've seen from Merck is really nothing more than an act of desperation. When you have no science, you attack the victim.
The beat was based on a combination of strong top-line growth, increased equity income, and higher other revenue. Merck deserves credit for starting to take action to put itself back together again and investors are clearly taking up the story.
I felt like we had truth and the jury was paying attention. They had a very tough case to defend. The documents are very difficult for Merck.
He's an excellent candidate, ... Dick's long tenure here at Merck will make this is a smooth transition process.
Merck is not dumb. They're not in the business of losing money.
Merck acted responsibly, from researching Vioxx prior to approval in studies with almost 10,000 patients, to monitoring the medicine while it was on the market, to voluntarily withdrawing the medicine when it did. We based our decisions on the data from well controlled clinical trials.
Merck faces a challenge in future trials of addressing the company's behavior.
We want to pick a jury that will pay attention to the evidence and hold Merck to the truth. This case is really about whether drug companies have to tell the truth to the public, and Merck failed to do that.
Merck will remain a research-driven pharmaceutical company, but we need to change our approach to virtually every aspect of our business and we must act with a sense of urgency.
Basically, as an average person, I would have to prove some scientist at Merck or some CEO somewhere had made a determination to hurt me.
Merck is going to fight an uphill battle every time they step in the courtroom, ... They have a long legal harangue ahead of them.
I think it's a decent choice, and with the challenges Merck faces, they needed someone who knows the company and knows the environment,
It's too soon to say Merck has momentum. Many people felt the Irvin case was a weak case to begin with. It was a short-term usage case.
We think the downside risk here is modest. Merck has fundamental challenges ahead based on its base business. We really concluded the stock is trading incorporating these items.
Merck, too, is down on recent news, down in this case from around 85, ... You keep hearing a little bit of concern about their patent expirations over the next two years. Those are very real. But most of analysts say their drug pipeline is pretty solid and their earnings are project to be some 15-to-18 percent for the next couple of years. This is a great investment with which to balance out your high-tech holdings.